Colomer Gould Veronica F
Department of Psychiatry, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA.
NeuroRx. 2005 Jul;2(3):480-3. doi: 10.1602/neurorx.2.3.480.
Machado-Joseph disease (MJD), also called spinocerebellar ataxia type 3, is caused by mutant ataxin-3 with a polyglutamine expansion. Although there is no treatment available at present to cure or delay the onset of MJD, mouse models have been generated to facilitate the development of a therapy. In this review, the published reports on mouse models of MJD and other polyglutamine spinocerebellar ataxias are compared. Based on these studies, the following approaches will be discussed as candidate treatments for MJD: 1) interfering with the formation of the mutant ataxin-3 cleavage fragment and possibly aggregate or inclusions, 2) reducing the disease protein nuclear localization, and 3) decreasing mutant ataxin-3 expression in neurons.
马查多-约瑟夫病(MJD),也称为3型脊髓小脑共济失调,由具有多聚谷氨酰胺扩增的突变型ataxin-3引起。尽管目前尚无治愈或延缓MJD发病的治疗方法,但已建立了小鼠模型以促进治疗方法的开发。在本综述中,对已发表的关于MJD和其他多聚谷氨酰胺脊髓小脑共济失调小鼠模型的报告进行了比较。基于这些研究,将讨论以下作为MJD候选治疗方法的途径:1)干扰突变型ataxin-3裂解片段的形成以及可能的聚集或包涵体形成,2)减少疾病蛋白的核定位,3)降低神经元中突变型ataxin-3的表达。